SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects ( nā=ā115) and were absent in the negative controls. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. ![]() ![]() ![]() Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |